Kurashiki Central Hospital Implements Medidata’s Rave Companion Solution to Reduce Complexity of Clinical Research Data
- Medidata will deliver “first of its kind” solution in Asia, enabling the hospital to increase the efficiency of clinical trials and facilitate the rapid development of new treatments through technology
- Medidata Rave Companion addresses the increasing burden of manual data entry on clinical trial sites and resulting data errors
- Pilot test of Rave Companion confirmed a reduction in the time required to enter data from electronic health records and other sources into Medidata Rave EDC (electronic data capture), with a 36% reduction in the query rate and data entry time required per field has been reduced by 19%.
Tokyo – Medidata Solutions K.K. (Medidata), a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Kurashiki Central Hospital, one of the largest clinical trial facilities in the Chugoku and Shikoku regions of Japan, today announced that Medidata Rave Companion has been fully installed in the hospital as of January 2024. This rollout of Rave Companion is the first of its kind in Japan.
Rave Companion automatically captures data from electronic health records and worksheets into Medidata Rave EDC instead of the traditional method of switching back and forth between windows while referencing source documents. Data can now be captured into Rave EDC forms with a few clicks, significantly reducing the time and effort required for manual entry, which has been a long-standing industry challenge. Rave EDC is the most advanced and robust EDC system for clinical trials, capturing, managing, cleaning and reporting site-, patient- and lab-reported data.
Like other clinical trial facilities, Kurashiki Central Hospital faced challenges due to the increasing complexity of clinical trial designs and the growing volume of information collected. This led to a proportional increase in the amount of work required for data entry and in ensuring clinical trial data accuracy.
Ohara HealthCare Foundation Kurashiki Central Hospital Clinical Research Center, Clinical Research Coordination Unit, participated in Medidata’s Early Adopter Program and conducted a pilot test in November 2023 to confirm the impact and benefits of using Rave Companion. Test results show both the total entry time and the percentage of queries decreasing after implementing the solution.
Ms. Eiko Nakagawa, Director of the Ohara HealthCare Foundation Clinical Research Center at Kurashiki Central Hospital, said, "While we were considering the use of electronic data for source documents, we decided to implement Rave Companion because it enables us to reduce the number of transcription errors when transferring clinical trial data to Rave EDC, thus improving efficiency. As the volume of data in clinical trials is expected to increase, we want to work towards ensuring that clinical trials can be conducted reliably with the optimal resources.”
Motohide Nishi, Vice President, Japan Sales, Life Science, Medidata, said, “We are pleased that Rave Companion has proven effective and useful in clinical trials in Kurashiki Central Hospital. Medidata is committed to improving the efficiency of clinical trials and facilitating the rapid development of new treatments through technology.”
With these results in hand, the hospital expanded its collaboration with Medidata from a test use only to a full-scale implementation of Rave Companion.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at https://www.medidata.com/jp/ and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit https://www.3ds.com (English).
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
Media Contact
Medidata Solutions
PR Agency
Fleishman-Hillard Japan
Yoshihiko Ninagawa
yoshihiko.ninagawa@fleishman.com
+81-70-2189-1403